In vivo RNAi-mediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells.
Courties G, Seiffart V, Presumey J, Escriou V, Scherman D, Zwerina J, Ruiz G, Zietara N, Jablonska J, Weiss S, Hoffmann A, Jorgensen C, Apparailly F, Gross G.
Courties G, et al. Among authors: scherman d.
Blood. 2010 Nov 4;116(18):3505-16. doi: 10.1182/blood-2010-02-269605. Epub 2010 Aug 3.
Blood. 2010.
PMID: 20682854
Free article.